Entrada Therapeutics, Inc.
TRDA
$8.16
-$0.168-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.63% | -55.25% | 421.16% | 134.05% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.63% | -55.25% | 421.16% | 134.05% | -- |
| Cost of Revenue | 18.08% | 40.85% | 21.81% | 23.83% | 80.37% |
| Gross Profit | -70.55% | -154.25% | 870.71% | 1,313.90% | 186.43% |
| SG&A Expenses | 13.95% | 32.38% | 13.06% | 18.41% | -12.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.11% | 38.71% | 19.73% | 22.45% | 44.43% |
| Operating Income | -219.61% | -254.57% | 427.77% | 465.28% | 119.18% |
| Income Before Tax | -108.04% | -187.98% | 578.35% | 910.98% | 137.34% |
| Income Tax Expenses | -109.98% | 89.31% | -80.08% | -48.44% | -- |
| Earnings from Continuing Operations | 111.85% | -139.57% | 312.25% | 452.05% | 61.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.85% | -139.57% | 312.25% | 452.05% | 61.25% |
| EBIT | -219.61% | -254.57% | 427.77% | 465.28% | 119.18% |
| EBITDA | -186.42% | -239.57% | 448.98% | 520.82% | 122.52% |
| EPS Basic | 109.69% | -132.42% | 305.94% | 440.16% | 63.59% |
| Normalized Basic EPS | -106.56% | -172.08% | 564.08% | 883.75% | 135.09% |
| EPS Diluted | 107.17% | -134.31% | 298.26% | 423.81% | 63.59% |
| Normalized Diluted EPS | -106.21% | -175.32% | 546.73% | 854.56% | 135.09% |
| Average Basic Shares Outstanding | 22.40% | 22.08% | 3.07% | 3.47% | 6.43% |
| Average Diluted Shares Outstanding | 29.01% | 16.83% | 7.07% | 7.46% | 6.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |